Central European Journal of Immunology
eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Share:
Send email
Share:
Original paper

Inhibition of XPOT promotes breast cancer cell pyroptosis to suppress cancer progression

Meng Liang
1
,
Min Wang
1
,
Beibei Zhu
2

  1. The Third Affiliated Hospital of Zhejiang Chinese Medical University, China
  2. The First Affiliated Hospital of Jinan University, China
Cent Eur J Immunol 2025
DOI: https://doi.org/10.5114/ceji.2025.154514
Online publish date: 2025/09/24
Article file
- Inhibition of XPOT.PDF  [1.34 MB]
Get citation
 
PlumX metrics:
 
1. Barzaman K, Karami J, Zarei Z, et al. (2020): Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol 84: 106535.
2. Katsura C, Ogunmwonyi I, Kankam HK, et al. (2022): Breast cancer: presentation, investigation and management. Br J Hosp Med (Lond) 83: 1-7.
3. Kolak A, Kamińska M, Sygit K, et al. (2017): Primary and secondary prevention of breast cancer. Ann Agric Environ Med 24: 549-553.
4. Akram M, Iqbal M, Daniyal M, et al. (2017): Awareness and current knowledge of breast cancer. Biol Res 50: 33.
5. Zhang YN, Xia KR, Li CY, et al. (2021): Review of breast cancer pathological image processing. Biomed Res Int 2021: 1994764.
6. Rao Z, Zhu Y, Yang P, et al. (2022): Pyroptosis in inflammatory diseases and cancer. Theranostics 12: 4310-4329.
7. Fang Y, Tian S, Pan Y, et al. (2020): Pyroptosis: A new frontier in cancer. Biomed Pharmacother 121: 109595.
8. Coll RC, Schroder K, Pelegrín P (2022): NLRP3 and pyroptosis blockers for treating inflammatory diseases. Trends Pharmacol Sci 43: 653-668.
9. Li Y, Song W, Tong Y, et al. (2021): Isoliquiritin ameliorates depression by suppressing NLRP3-mediated pyroptosis via miRNA-27a/SYK/NF-B axis. J Neuroinflammation 18: 1.
10. Chen T, Meng Y, Zhou Z, et al. (2023): GAS5 protects against nonalcoholic fatty liver disease via miR-28a-5p/MARCH7/NLRP3 axis-mediated pyroptosis. Cell Death Differ 30: 1829-1848.
11. Yu S, Zhao N, He M, et al. (2020): MiRNA-214 promotes the pyroptosis and inhibits the proliferation of cervical cancer cells via regulating the expression of NLRP3. Cell Mol Biol (Noisy-le-grand) 66: 59-64.
12. Wang JG, Jian WJ, Li Y, et al. (2021): Nobiletin promotes the pyroptosis of breast cancer via regulation of miR-200b/JAZF1 axis. Kaohsiung J Med Sci 37: 572-582.
13. Wang JL, Hua SN, Bao HJ, et al. (2023): Pyroptosis and inflammasomes in cancer and inflammation. MedComm 4: e374.
14. Exconde PM, Hernandez-Chavez C, Bourne CM, et al. (2023): The tetrapeptide sequence of IL-18 and IL-1 regulates their recruitment and activation by inflammatory caspases. Cell Rep 42: 113581.
15. Cheung CY, Huang TT, Chow N, et al. (2022): Unconventional tonicity-regulated nuclear trafficking of NFAT5 mediated by KPNB1, XPOT and RUVBL2. J Cell Sci 135: jcs259280.
16. Gupta A, Kailasam S, Bansal M (2016): Insights into the Structural Dynamics of Nucleocytoplasmic Transport of tRNA by Exportin-t. Biophys J 110: 1264-1279.
17. Pan LJ, Chen JL, Wu ZX, et al. (2021): Exportin-T: A novel prognostic predictor and potential therapeutic target for neuroblastoma. Technol Cancer Res Treat 20: 15330338211039132.
18. Lin J, Hou Y, Huang S, et al. (2019): Exportin-T promotes tumor proliferation and invasion in hepatocellular carcinoma. Mol Carcinog 58: 293-304.
19. Suzuki T, Koyama Y, Hayakawa S, et al. (2006): 1,25-Dihydroxyvitamin D3 suppresses exportin expression in human promyelocytic leukemia HL-60 cells. Biomed Res 27: 89-92.
20. Mehmood R, Jibiki K, Shibazaki N, et al. (2021): Molecular profiling of nucleocytoplasmic transport factor genes in breast cancer. Heliyon 7: e06039.
21. Wen HY, Collins LC (2023): Breast cancer pathology in the era of genomics. Hematol Oncol Clin North Am 37: 33-50.
22. Goel S, Chandarlapaty S (2023): Emerging therapies for breast cancer. Cold Spring Harb Perspect Med 13: a041333.
23. Kisely S, Alotiby MKN, Protani MM, et al. (2023): Breast cancer treatment disparities in patients with severe mental illness: A systematic review and meta-analysis. Psychooncology 32: 651-662.
24. Cardoso MJ, Poortmans P, Senkus E, et al. (2024): Breast cancer highlights from 2023: Knowledge to guide practice and future research. Breast 74: 103674.
25. Yan S, Wang W, Zhu B, et al. (2020): Construction of nomograms for predicting pathological complete response and tumor shrinkage size in breast cancer. Cancer Manag Res 12: 8313-8323.
26. Li H, Shi W, Shen T, et al. (2023): Network pharmacology-based strategy for predicting therapy targets of Ecliptae Herba on breast cancer. Medicine 102: e35384.
27. Kong Z, Han Q, Zhu B, et al. (2023): Circ_0069094 regulates malignant phenotype and paclitaxel resistance in breast cancer cells via targeting the miR-136-5p/YWHAZ axis. Thorac Cancer 14: 1831-1842.
28. Liu J, Hong M, Li Y, et al. (2022): Programmed cell death tunes tumor immunity. Front Immunol 13: 847345.
29. Kopeina GS, Zhivotovsky B (2022): Programmed cell death: Past, present and future. Biochem Biophys Res Commun 633: 55-58.
30. Wang M, Yu F, Zhang Y, et al. (2024): Programmed cell death in tumor immunity: mechanistic insights and clinical implications. Front Immunol 14: 1309635.
31. Yu W, Qin X, Zhang Y, et al. (2020): Curcumin suppresses doxorubicin-induced cardiomyocyte pyroptosis via a PI3K/Akt/mTOR-dependent manner. Cardiovasc Diagn Ther 10: 752-769.
32. Lei S, Li S, Xiao W, et al. (2023): Azurocidin 1 inhibits the aberrant proliferation of triple negative breast cancer through the regulation of pyroptosis. Oncol Rep 50: 188.
33. Sang R, Fan R, Deng A, et al. (2023): Degradation of hexokinase 2 blocks glycolysis and induces GSDME-dependent pyroptosis to amplify immunogenic cell death for breast cancer therapy. J Med Chem 66: 8464-8483.
34. Chen C, Ye Q, Wang L, et al. (2023): Targeting pyroptosis in breast cancer: Biological functions and therapeutic potentials on It. Cell Death Dis 9: 75.
35. Dai H, Yang X, Sheng X, et al. (2023): XPOT disruption suppresses TNBC growth through inhibition of specific tRNA nuclear exportation and TTC19 expression to induce cytokinesis failure. Int J Biol Sci 19: 5319-5336.
36. Chen L, Huang Y, Zhou L, et al. (2019): Prognostic roles of the transcriptional expression of exportins in hepatocellular carcinoma. Biosci Rep 39: BSR20190827.
37. Verma A, Cohen DJ, Schwartz N, et al. (2019): 24R, 25-dihydroxyvitamin D3 regulates breast cancer cells in vitro and in vivo. Biochim Biophys Acta 1863: 1498-1512.
38. Takouda J, Nakamura M, Murasaki A, et al. (2024): Identification of azalamellarin N as a pyroptosis inhibitor. Biol Pharm Bull 47: 28-36.
39. Cheng WZ, Wei-Hua WA, Ai-Ping DE, et al. (2023): Identification of an LDLR variant in a Chinese familial hypercholesterolemia and its relation to ROS/NLRP3-mediated pyroptosis in hepatic cells. J Geriatr Cardiol 20: 341-349.
40. Zhang Z, Ni P, Tang M, et al. (2023): Dapagliflozin alleviates renal podocyte pyroptosis via regulation of the HO 1/NLRP3 axis. Mol Med Rep 28: 200.
Copyright: © 2025 Polish Society of Experimental and Clinical Immunology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.